Thursday, April 9, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Analysis

F&G Annuities & Life Reports Sharp Decline in Quarterly Profit Amid Record Assets

SiterGedge by SiterGedge
February 22, 2026
in Analysis, Banking & Insurance, Earnings
0
F G Annuities Life Stock
0
SHARES
9
VIEWS
Share on FacebookShare on Twitter

F&G Annuities & Life has presented a mixed financial picture for its latest reporting period. The company announced a significant contraction in profitability for the fourth quarter of 2025, even as assets under management reached a new peak, creating a complex scenario for investors.

Profitability Under Pressure

The insurer’s net income for Q4 2025 fell dramatically to $124 million, or $0.92 per share. This result marks a drop of more than 60% from the $323 million earned in the same quarter the previous year. Adjusted net earnings also disappointed, coming in at $0.91 per share and missing market forecasts.

For the full 2025 fiscal year, net profit stood at $248 million. This figure represents a substantial decline from the $622 million reported for the prior year. Annual revenue remained largely unchanged at $5.73 billion. The stark divergence between asset growth and earnings performance raises questions about the company’s near-term profit trajectory.

Strategic Shift and Capital Management

In response to these challenges, management is executing a strategic repositioning. The initiative aims to improve capital efficiency and grow the proportion of fee-based revenue. A key component of this plan is the pending sale of the Bermuda-based subsidiary, F&G Life Re. That transaction is anticipated to close in March 2026, with expected net proceeds of approximately $300 million.

Should investors sell immediately? Or is it worth buying F G Annuities Life?

The company’s capital position remains robust, with a Risk-Based Capital Ratio of 430%, well above internal target levels. Shareholders will receive a quarterly dividend of $0.25 per share, scheduled for payment on March 31, 2026. Following the earnings release, the analysis firm Wall Street Zen downgraded the stock to a “Hold” rating.

Record Funds Under Management Contrast with Earnings

Operational metrics told a more positive story. F&G Annuities posted strong growth in its core business, with assets under management climbing 12% year-over-year to a record $73.1 billion. Full-year gross sales were a robust $14.6 billion, indicating powerful net inflows.

The quality of the investment portfolio remained high, with 97% of fixed-income securities holding an investment-grade rating. This growth in managed assets, however, stood in sharp contrast to the declining earnings, highlighting the current pressures on the company’s bottom line.

Ad

F G Annuities Life Stock: Buy or Sell?! New F G Annuities Life Analysis from April 9 delivers the answer:

The latest F G Annuities Life figures speak for themselves: Urgent action needed for F G Annuities Life investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from April 9.

F G Annuities Life: Buy or sell? Read more here...

Tags: F G Annuities Life
SiterGedge

SiterGedge

Related Posts

DeFi Technologies Stock
Blockchain

DeFi Technologies Navigates Record Profits and Listing Compliance Challenge

April 8, 2026
Puma Stock
Analysis

Puma’s Rocky Road to Recovery: Legal Windfall Meets Operational Headwinds

April 8, 2026
Canopy Growth Stock
Analysis

Canopy Growth Shows Significant Financial Progress as Losses Narrow

April 8, 2026
Next Post
Stellus Capital Investment Stock

Key Dates and Strategic Focus for Stellus Capital Investors

Gabelli Multimedia Stock

Gabelli Multimedia Trust Expands Equity Offering Program

Nexalin Technology Stock

The Clinical Pathway for Nexalin Technology's Neurostimulation Platform

Recommended

Robinhood Stock

Robinhood Faces Strategic Challenge as Coinbase Moves Into Prediction Markets

4 months ago
Diginex Stock

Diginex Shares Plummet Amid Strategic AI Expansion

5 months ago
Rocket Lab USA Stock

Rocket Lab Shares Surge on Major Government Grant and Operational Milestones

8 months ago
M&T Bank Stock

M&T Bank Shares: Can Strong Fundamentals Overcome Market Weakness?

6 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Bloom Energy Broadcom Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Salesforce Strategy Synopsys Take-Two Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Canopy Growth Shows Significant Financial Progress as Losses Narrow

Eutelsat Shares Surge on Back of Major EU Satellite Initiative

Worthington Steel Moves Toward Full Control of Klöckner & Co

Erste Bank Shareholders Face Crucial Vote Amid Integration Challenges

LVMH’s U.S. Manufacturing Strategy Faces a Stress Test

Green Bridge Metals: Key Catalysts Emerge Amid High Copper Prices

Trending

DeFi Technologies Stock
Blockchain

DeFi Technologies Navigates Record Profits and Listing Compliance Challenge

by Jackson Burston
April 8, 2026
0

DeFi Technologies Inc. finds itself at a pivotal crossroads, having just reported its most successful fiscal year...

Puma Stock

Puma’s Rocky Road to Recovery: Legal Windfall Meets Operational Headwinds

April 8, 2026
Refined Energy Stock

Refined Energy Nears Key Milestone with Warrant Lock-Up Expiry

April 8, 2026
Canopy Growth Stock

Canopy Growth Shows Significant Financial Progress as Losses Narrow

April 8, 2026
Eutelsat Stock

Eutelsat Shares Surge on Back of Major EU Satellite Initiative

April 8, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • DeFi Technologies Navigates Record Profits and Listing Compliance Challenge
  • Puma’s Rocky Road to Recovery: Legal Windfall Meets Operational Headwinds
  • Refined Energy Nears Key Milestone with Warrant Lock-Up Expiry

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com